Biotechnology

Found 39,849 articles

• Prime Medicine to Present at Investor Conferences in June 2023

  5/31/2023

  Prime Medicine, Inc., a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, announced that Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine, will participate in three investor conferences in June.

• IGM Biosciences Announces FDA Clearance to Begin Clinical Studies of Imvotamab in Lupus and Rheumatoid Arthritis

  5/31/2023

  IGM Biosciences, Inc. announced that the U.S. Food and Drug Administration has cleared two Investigational New Drug applications for imvotamab, an IgM-based CD20 X CD3 bispecific antibody T cell engager, enabling the initiation of Phase 1b studies in both severe systemic lupus erythematosus and severe rheumatoid arthritis.

• AltruBio to Present at the 2023 BIO International Convention

  5/31/2023

  AltruBio Inc. announced that President and Chief Executive Officer Judy Chou, Ph.D., will present an in-person corporate overview at the 2023 BIO International Convention taking place June 5-8, 2023, in Boston, MA.

• Cabaletta Bio to Present at the 2023 Jefferies Healthcare Conference

  5/31/2023

  Cabaletta Bio, Inc. announced that Steven Nichtberger, M.D., Chief Executive Officer, will present a company presentation at the Jefferies Healthcare Conference on Wednesday, June 7, 2023 at 10:30 a.m. ET in New York, NY.

• Invitae to Present at the William Blair 43rd Annual Growth Stock Conference

  5/31/2023

  Invitae, a leading medical genetics company, announced that Ken Knight, president and chief executive officer, will present at the William Blair 43rd Annual Growth Stock Conference on Wednesday, June 7, 2023, at 12:40 p.m. Central Time.

• Akero Therapeutics to Present at the Jefferies 2023 Healthcare Conference

  5/31/2023

  Akero Therapeutics, Inc. announced that management will present at the Jefferies Healthcare Conference Wednesday, June 7, 2023, at 10:30 a.m. in New York, NY.

• Selecta Biosciences Announces Presentation of Data from Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout During Late-Breaking Session at the EULAR 2023 European Congress of Rheumatology

  5/31/2023

  Selecta Biosciences, Inc. (NASDAQ: SELB) today announced the presentation of positive data from the Phase 3 DISSOLVE I and DISSOLVE II double-blind, placebo-controlled studies of SEL-212 in patients with chronic refractory gout.

• BioAtla to Participate in the 2023 Jefferies Healthcare Conference

  5/31/2023

  BioAtla, Inc. announced that the Company’s management will participate in a fireside chat and scheduled one-on-one investor meetings at the Jefferies Healthcare Conference, to be held in New York, NY June 7-9, 2023.

• Evaxion Announces Business Update and First Quarter 2023 Financial Results

  5/31/2023

  Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, announced today its first quarter 2023 financial results and provided a business update.

• Jnana Therapeutics Reports Positive Topline Results from Phase 1a Clinical Study of JNT-517, a Potential First-in-Class Oral Treatment for PKU

  5/31/2023

  Jnana Therapeutics today announced positive topline results from the Phase 1a clinical trial of JNT-517 in healthy volunteers.

• Willow Signs Master Services Agreement With Innovative Biotech Company to Develop Ingredients for Age-related Diseases

  5/31/2023

  Willow Biosciences Inc., a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable functional ingredients announces execution of a Master Services Agreement with an innovative biotech company focused on age-related diseases.

• Cellectis Publishes an Article in Cancer Immunology Research Demonstrating Preclinical Evidence of UCART20x22 Product Candidate to Target a Broad Spectrum of Patients with B-cell Malignancies

  5/31/2023

  Cellectis today publishes an article in Cancer Immunology Research demonstrating pre-clinical proof-of-concept data of UCART20x22 product candidate, Cellectis’ first allogeneic dual CAR T-cell targeting the CD20 and CD22 antigens.

• Repligen Corporation to Present at Upcoming June 2023 Investor Conferences

  5/31/2023

  Repligen Corporation, a life sciences company focused on bioprocessing technology leadership, announced that it will be presenting at two upcoming investor conferences.

• Abcuro Completes Enrollment of Sentinel Cohort in Phase 2/3 Study of ABC008 for the Treatment of Inclusion Body Myositis

  5/31/2023

  Abcuro, Inc. today announced completion of enrollment of the sentinel cohort of a Phase 2/3 study of ABC008 for the treatment of inclusion body myositis (IBM).

• Erasca to Host Virtual Investor Event on Pipeline Updates with a Focus on ERAS-007 ERK Inhibitor

  5/31/2023

  Erasca, Inc. announced it will host a virtual investor event on Erasca pipeline updates on Monday, June 5, 2023, at 4:30 PM ET.

• AffaMed Therapeutics Announces Completion of Patient Enrollment in the Real-World Study in China Evaluating the Safety and Efficacy of DEXTENZA® in Cataract Surgery Patients

  5/31/2023

  AffaMed Therapeutics today announced the completion of patient enrollment in the Real-World Study ("RWS") conducted in the Boao Lecheng Pilot Zone in Hainan, China, to evaluate the safety and efficacy of DEXTENZA® (0.4 mg dexamethasone ophthalmic insert) for the treatment of ocular inflammation and pain following cataract surgery.  

• Liberate Bio Announces Expansion of its Leadership Team

  5/31/2023

  Liberate Bio., a biotech company focused on identifying and developing new vehicles to deliver oligonucleotide cargos, announced the expansion of its leadership team.

• Adiso Therapeutics Announces the Completion of a Phase 1b Multiple Ascending Dose Study of ADS051 for the Treatment of Moderately-to-Severely Active Ulcerative Colitis

  5/31/2023

  Adiso Therapeutics, Inc. today announced the completion of a Phase 1b multiple ascending dose (MAD) clinical trial evaluating ADS051 (BT051) an oral, gut-restricted, small molecule modulator of neutrophil trafficking and activation.

• AI Proteins Announces the Formation of a Scientific Advisory Board Made up of Experts in Biotech and FDA Drug Approval

  5/31/2023

  AI Proteins, Inc., a growing biotechnology company that utilizes computational de novo protein design to create novel therapeutic miniproteins, today announced the formation of a Scientific Advisory Board.

• Biostage Initiated Study Start-up Activities for Clinical Trial in Severe Esophageal Disease

  5/31/2023

  Biostage, Inc. a clinical-stage biotechnology company developing the technology to regenerate organs inside the body to treat severe diseases, including cancer, trauma and birth defects initially in the esophagus and the airway, today announced that it initiated start-up activities for its first clinical trial.